Dr Dan Knight

Job title

Consultant cardiologist

Related services

Biography

Dr Dan Knight is Clinical Lead of the national pulmonary hypertension (PH) service at the Royal Free Hospital, one of seven specialist centres in the United Kingdom for the management of adult PH.

He is a Consultant Cardiologist at the Royal Free London NHS Foundation Trust and Honorary Associate Professor at the Institute of Cardiovascular Science, University College London (UCL).

As a clinical academic consultant cardiologist, his research has been supported by two British Heart Foundation (BHF) Fellowships (2021-2024, 2025-2030) and the UCLH Biomedical Research Centre (BRC, 2018-2021). His research uses innovative CMR-based techniques applied to patients with PH and systemic sclerosis.

These include MRI-guided right heart catheterisation, cardiac MRI-cardiopulmonary exercise testing (CMR-CPET) and advanced CMR tissue characterization. CMR-guided right heart catheterisation is now routinely performed as a weekly list in the Royal Free PH service.

Several international PH and CMR services have attended our CMR-RHC workshops, following which they have gone on to set up their own MRI-guided right heart catheterisation programs. He is currently leading the new NIHR low-field MRI research scanner at the Royal Free, opened in 2025.

Dr Knight is also co-training program director (TPD) for academic medical specialties in London, cardiovascular research lead at the Royal Free Hospital, and was the former Research Specialty Lead for the NIHR North Thames Cardiovascular Clinical Research Network.

GMC number

6104083

I have authored or co-authored 78 peer-reviewed publications. Selected first or last author publications include:

1. Prognostic utility of exercise CMR in patients with systemic sclerosis-associated pulmonary arterial hypertension. Eur Heart J Cardiovasc Imaging. 2024;25(12):1712-1720. doi: 10.1093/ehjci/jeae177.

2. Native myocardial T1 and right ventricular size by CMR predict outcome in systemic sclerosis-associated pulmonary hypertension. Rheumatology (Oxford). 2024;63(10):2678-2683. doi: 10.1093/rheumatology/keae141.

3. Pulmonary hypertension – latest updates for physicians. Clin Med. 2023;23(5):449-454. doi: 10.7861/clinmed.2023-23.5.Cardio4.

4. Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2023;24(4):463-471. doi: 10.1093/ehjci/jeac120.

5. Ongoing exercise intolerance following COVID-19: a magnetic resonance-augmented cardiopulmonary exercise study. J Am Heart Assoc. 2022;11(9):e024207. doi: 10.1161/JAHA.121.024207.

6. Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study. J Cardiovasc Magn Reson. 2021;23(1):118. doi: 10.1186/s12968-021-00817-1.

7. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021;42(19):1866-1878. doi: 10.1093/eurheartj/ehab075.

8. COVID-19: Myocardial injury in survivors. Circulation. 2020;142(11):1120-1122. doi: 10.1161/CIRCULATIONAHA.120.049252.

9. Echocardiographic Assessment of the Right Heart in Adults. A guideline protocol from the British Society of Echocardiography Education Committee. Echo Res Pract. 2020;7(1):G19-G41. doi: 10.1530/ERP-19-0051.

10. Cardiovascular magnetic resonance-guided right heart catheterization in a conventional CMR environment – predictors of procedure success and duration in pulmonary hypertension. J Cardiovasc Magn Reson. 2019;21(1):57. doi: 10.1186/s12968-019-0569-9.

11. Cardiac structural and functional consequences of amyloid deposition by CMR and echocardiography and their prognostic roles. JACC Cardiovasc Imaging. 2019;12(5):823-833. doi: 10.1016/j.jcmg.2018.02.016.

  • Cardiovascular involvement in systemic sclerosis
  • MRI-guided right heart catheterisation in pulmonary hypertension
  • Exercise cardiac MRI
  • Low-field MRI